ERBB2 and cholangiocarcinoma: In a phase II trial evaluating the combination of pertuzumab and trastuzumab in HER2-positive previously treated CCA cases, this combination therapy achieved an ORR of 23.1%, a median PFS of 4.0 months, and a median OS of 10.9 months (Table 2) [58].